We are live on ! Find out more
AIP

Arrowpoint Investment Partners Portfolio holdings

AUM $113M
1-Year Est. Return 73.91%
This Fund
S&P 500
This Quarter Est. Return
+9.13%
1 Year Est. Return
+73.91%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$113M
AUM Growth
-$566M
Cap. Flow
-$573M
Cap. Flow %
-509.53%
Top 10 Hldgs %
59.57%
Holding
143
New
38
Increased
22
Reduced
20
Closed
61

Top Buys

Rank Stock Value
1
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$9.34M
2
ASX icon
ASE Group
ASX
+$3.77M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$2.84M
4
AXSM icon
Axsome Therapeutics
AXSM
+$2.47M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$2.39M

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$82.5M
2
JNJ icon
Johnson & Johnson
JNJ
+$71.3M
3
MSFT icon
Microsoft
MSFT
+$70.1M
4
C icon
Citigroup
C
+$54.1M
5
HD icon
Home Depot
HD
+$54M

Sector Composition

Rank Sector Weight
1 Healthcare 42.66%
2 Communication Services 8.03%
3 Technology 3.81%
4 Financials 0.8%
5 Materials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IGV icon
1
CALL
iShares Expanded Tech-Software Sector ETF
IGV
$13.8B
$18.5M 16.42%
+230,800
New +$20.4M
KWEB icon
2
CALL
KraneShares CSI China Internet ETF
KWEB
$5.32B
$11.4M 10.11%
+400,000
New +$13.1M
GOOGL icon
3
Alphabet (Google) Class A
GOOGL
$4.23T
$8.95M 7.96%
31,127
+29,727
+2,123% +$9.34M
SMH icon
4
PUT
VanEck Semiconductor ETF
SMH
$67.5B
$8.43M 7.49%
+22,000
New +$8.74M
EWZ icon
5
CALL
iShares MSCI Brazil ETF
EWZ
$9.1B
$4.61M 4.09%
+120,000
New +$4.39M
ASX icon
6
ASE Group
ASX
$84.3B
$3.89M 3.46%
+179,512
New +$3.77M
IONS icon
7
Ionis Pharmaceuticals
IONS
$8.99B
$2.93M 2.6%
38,988
+13,971
+56% +$1.1M
NBIX icon
8
Neurocrine Biosciences
NBIX
$17.2B
$2.84M 2.52%
21,556
+18,039
+513% +$2.39M
AXSM icon
9
Axsome Therapeutics
AXSM
$11.8B
$2.77M 2.46%
16,401
+14,291
+677% +$2.47M
BMRN icon
10
BioMarin Pharmaceuticals
BMRN
$11.5B
$2.75M 2.45%
+48,719
New +$2.84M
ASND icon
11
Ascendis Pharma A/S
ASND
$17.1B
$2.71M 2.4%
11,828
+8,831
+295% +$1.98M
PTCT icon
12
PTC Therapeutics
PTCT
$6.52B
$2.7M 2.4%
39,701
+30,463
+330% +$2.16M
PFE icon
13
Pfizer
PFE
$143B
$2M 1.78%
71,313
+27,971
+65% +$745K
REGN icon
14
Regeneron Pharmaceuticals
REGN
$70.9B
$1.93M 1.72%
2,502
+964
+63% +$738K
JNJ icon
15
Johnson & Johnson
JNJ
$609B
$1.93M 1.72%
7,902
-306,027
-97% -$71.3M
AMGN icon
16
Amgen
AMGN
$198B
$1.74M 1.54%
4,934
-1,025
-17% -$365K
GILD icon
17
Gilead Sciences
GILD
$167B
$1.67M 1.48%
11,961
-7,458
-38% -$1.04M
VRTX icon
18
Vertex Pharmaceuticals
VRTX
$123B
$1.52M 1.35%
3,412
+48
+1% +$22.4K
UNH icon
19
UnitedHealth
UNH
$387B
$1.41M 1.25%
+5,216
New +$1.55M
PRAX icon
20
Praxis Precision Medicines
PRAX
$8.77B
$1.24M 1.1%
3,855
+1,773
+85% +$548K
INSM icon
21
Insmed
INSM
$23.5B
$1.15M 1.02%
7,018
-4,538
-39% -$698K
PTGX icon
22
Protagonist Therapeutics
PTGX
$9.06B
$984K 0.87%
+9,334
New +$826K
BLTE
23
Belite Bio
BLTE
$6.02B
$957K 0.85%
6,004
+2,955
+97% +$497K
EWT icon
24
iShares MSCI Taiwan ETF
EWT
$9.94B
$887K 0.79%
+12,500
New +$879K
MRNA icon
25
Moderna
MRNA
$24.5B
$869K 0.77%
+17,097
New +$798K
1
2 3 4 5

Similar funds

MWP
Momentum Wealth Planning Estero, Florida $113M AUM 26.08% 1-Year Est. Return
AIC
Argus Investors Counsel New York $112M AUM 25.83% 1-Year Est. Return
OP
Oath Planning Tulsa, Oklahoma $113M AUM
VCM
Veradace Capital Management Dallas, Texas $112M AUM
TBNY
Trustco Bank (New York) Albany, New York $113M AUM 34.59% 1-Year Est. Return
GCWM
Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return
PFS
Professional Financial Solutions Falls Chruch, Virginia $112M AUM
UOWF
University of Wisconsin Foundation Madison, Wisconsin $113M AUM 23.15% 1-Year Est. Return

Arrowpoint Investment Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Arrowpoint Investment Partners held 143 positions worth $113M, down 83% from $679M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Arrowpoint Investment Partners withdrew a net $573M in Q1 2026, closing 61 positions and reducing 20 holdings. Its most notable exit was NVIDIA, an estimated $82.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 18% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Arrowpoint Investment Partners opened a new position in ASE Group worth $3.89M.

  • Arrowpoint Investment Partners's largest Q1 2026 buy was ASE Group: 179,512 shares worth $3.89M.
  • Arrowpoint Investment Partners added most to Alphabet (Google) Class A in Q1 2026, an estimated $9.34M increase.
  • Arrowpoint Investment Partners's biggest Q1 2026 reduction was Johnson & Johnson, cutting an estimated $71.3M.
  • Arrowpoint Investment Partners fully exited NVIDIA in Q1 2026, selling an estimated $82.5M.
  • Arrowpoint Investment Partners's ten largest holdings make up 60% of its $113M portfolio in Q1 2026.
  • Arrowpoint Investment Partners opened 38 new positions and closed 61 in Q1 2026.
  • Arrowpoint Investment Partners's portfolio value fell 83% quarter-over-quarter to $113M.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.